Figure S1. Combination of Sora and Art does not show synergistic effects on hepatoxicity in normal primary human hepatocytes. The drug combination ratio of Sora:Art was fixed at (A) 1:50 or (B) 1:10. Cell growth inhibition was determined using the CyQUANT reagent at 72 h after drug treatment. Data are presented as the mean + standard deviation. ###P<0.001, Sora + Art vs. Sora. Sora, sorafenib; Art, artesunate.




Figure S2. Combinatorial inhibitory effect of Sora and Art on cell growth in liver cancer cells *in vitro*. (A) HepG2 and Huh7 cells were simultaneously treated with Sora, Art or Sora + Art at a constant ratio of Sora:Art (1:5) for 48 h. (B) Huh7 cells were sequentially treated with Art for 24 h and then Sora for 48 h at different concentrations. Cell growth inhibition was determined by a CyQUANT cell proliferation assay. Combination indices vs. fraction effects at the ED<sub>50</sub>, ED<sub>75</sub>, and ED<sub>90</sub> levels were calculated based on the growth inhibition curves. Data are presented as the means + standard deviation. \*\*\*P<0.001 compared with Sora, \*\*\*\*P<0.001 vs. Art. Sora, sorafenib; Art, artesunate; ED<sub>50</sub>, median effective dose to inhibit 50% of cells; ED<sub>75</sub>, median effective dose to inhibit 75% of cells; ED<sub>90</sub>, median effective dose to inhibit 90% of cells; N.D., not determined (did not comply with Calcusyn mathematical model).

